Aptinyx Inc reported $4.65M in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US USD 78.11M 11.79M
Acorda Therapeutics ACOR:US USD 23M 7.07M
Biogen BIIB:US USD 563.3M 9.3M
Cara Therapeutics CARA:US USD 6.88M 658K
Daiichi Sankyo 4568:JP JPY 120.96B 7.47B
Eli Lilly And LLY:US USD 1.64B 29M
Halozyme Therapeutics HALO:US USD 34.07M 23.41M
Intra Cellular Therapies ITCI:US USD 88.38M 11.94M
Marinus Pharmaceuticals MRNS:US USD 13.39M 3.67M
Neurocrine Biosciences NBIX:US USD 186.3M 3.5M
Novartis NOVN:VX USD 3.4B 185M
Ultragenyx Pharmaceutical RARE:US USD 69.84M 1.7M
Vertex Pharmaceuticals VRTX:US USD 246.8M 31.5M